Elanco Animal Health Incorporated $ELAN Shares Sold by Deutsche Bank AG

Key Points

• Deutsche Bank AG significantly decreased its holdings in Elanco Animal Health by 76.4%, reducing their shares from 1,037,077 to 244,542, which represents a value of $2.57 million at the end of the first quarter.
• During the same period, several institutional investors increased their stakes, with Allworth Financial LP raising its holdings by an impressive 791.7%.
• Elanco Animal Health's performance showed an earnings per share (EPS) of $0.26 for the most recent quarter, surpassing expectations, and the company anticipates an FY 2025 EPS in the range of 0.850 to 0.910.

Deutsche Bank AG lessened its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 76.4% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 244,542 shares of the company's stock after selling 792,535 shares during the quarter. Deutsche Bank AG's holdings in Elanco Animal Health were worth $2,568,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Allworth Financial LP boosted its stake in shares of Elanco Animal Health by 791.7% in the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after buying an additional 2,090 shares during the period. CoreCap Advisors LLC purchased a new position in shares of Elanco Animal Health in the 4th quarter valued at about $29,000. NBC Securities Inc. purchased a new position in shares of Elanco Animal Health in the 1st quarter valued at about $40,000. Parallel Advisors LLC boosted its stake in shares of Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after buying an additional 1,852 shares during the period. Finally, Versant Capital Management Inc boosted its stake in shares of Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after buying an additional 1,740 shares during the period. Hedge funds and other institutional investors own 97.48% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ELAN shares. Zacks Research cut Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 20th. Leerink Partnrs raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Stifel Nicolaus raised their target price on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Finally, Piper Sandler raised their target price on Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $17.33.

Elanco Animal Health Stock Down 0.6%

Shares of NYSE ELAN traded down $0.11 during midday trading on Monday, hitting $17.80. 3,523,651 shares of the company's stock were exchanged, compared to its average volume of 6,667,397. The company has a market cap of $8.84 billion, a PE ratio of 20.70, a P/E/G ratio of 3.32 and a beta of 1.66. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $18.08. The firm's fifty day simple moving average is $15.16 and its 200-day simple moving average is $12.52. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm's revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.